- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study consists of Phase 1a dose escalation, Phase 1b dose expansion in a single indication, and Phase 2a expansion in a single indication.
Primary Objectives
- All Phases: Evaluate the safety and tolerability of MDX2001 in patients with advanced solid tumor malignancies
- Phase 1 only: Identify a recommended Phase 2 dose (RP2D) for further development of MDX2001
- For Phase 1b and Phase 2: Assess the anti-tumor efficacy of MDX2001 in patients with selected advanced solid tumor malignancies
Secondary Objectives:
- Further characterize the anti-tumor activity of MDX2001 based on additional assessments of clinical benefit
- Characterize the pharmacokinetics of MDX2001
- Characterize the immunogenicity of MDX2001
- Characterize relationship of baseline target protein expression in tumor tissue and clinical benefit
The expected duration of study intervention for patients may vary, based on progression date. The median expected duration of study per patient is estimated to be 10 months (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Email recommended
- Phone Number: (857) 233-9936
- Email: info@modextx.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be ≥ 18 years of age
- Histologically or cytologically confirmed diagnosis of metastatic solid tumors
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- All patients should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
- All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Adequate hematologic, hepatic and renal function
- Capable of giving signed informed consent
Exclusion Criteria:
- Any clinically significant cardiac disease
- Unresolved toxicities from previous anticancer therapy
- Prior solid organ or hematologic transplant
- Known untreated, active, or uncontrolled brain metastases
- Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infectious requiring intravenous treatment.
- Receipt of a live-virus vaccination within 28 days of planned treatment start
- Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.
- Participation in a concurrent clinical study in the treatment period.
- Known hypersensitivity to MDX2001 or any of its ingredients
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1a - MDX2001 Dose Escalation
Patients with metastatic solid tumors will receive MDX2001 as intravenous (IV) infusion.
|
MDX2001 intravenous infusion
|
Experimental: Phase 1b - Dose Expansion - Dose A
Patients with a single tumor indication receive MDX2001 as intravenous (IV) infusion.
|
MDX2001 intravenous infusion
|
Experimental: Phase 1b - Dose Expansion - Dose B
Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion.
|
MDX2001 intravenous infusion
|
Experimental: Phase 2a - Cohort Expansion
Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion at the recommended Phase 2 dose.
|
MDX2001 intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Phases: Adverse events (AEs)
Time Frame: Baseline until end of study, up to approximately 9 months
|
Incidence and severity of AEs and serious AEs (SAEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 including changes in clinical laboratory parameters
|
Baseline until end of study, up to approximately 9 months
|
Phase 1b and Phase 2a: Objective response rate of MDX2001
Time Frame: From date of enrollment until the end of treatment, up to approximately 6 months
|
Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
|
From date of enrollment until the end of treatment, up to approximately 6 months
|
Phase 1: Recommended Phase 2 dose (RP2D)
Time Frame: Baseline until end of study, up to approximately 9 months
|
Recommended Phase 2 dose is determined following the evaluation of MDX2001 safety including the incidences of dose limiting toxicities (DLTs), MDX2001 anti-tumor activity, and MDX2001 pharmacokinetics
|
Baseline until end of study, up to approximately 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1a: Objective response rate of MDX2001
Time Frame: From date of enrollment until the end of treatment, up to approximately 6 months
|
Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per RECIST v1.1.
|
From date of enrollment until the end of treatment, up to approximately 6 months
|
All Phases: Duration of response (DOR)
Time Frame: From date of enrollment until the end of treatment, up to approximately 6 months
|
Duration of response is defined as the time from first documentation of response (complete response [CR] or partial response [PR]) to documentation of objective disease progression or death due to any cause, whichever occurs first
|
From date of enrollment until the end of treatment, up to approximately 6 months
|
All Phases: Time to response (TTR)
Time Frame: From date of enrollment until the first documentation of response (CR or PR), approximately 4 months
|
Time to response is defined as the time from first dose to first documentation of response (CR or PR)
|
From date of enrollment until the first documentation of response (CR or PR), approximately 4 months
|
All Phases: Disease control rate (DCR)
Time Frame: From date of enrollment until the end of treatment, up to approximately 6 months
|
Disease control rate is defined as the proportion of evaluable patients with a best overall response (BOR) of stable disease, CR or PR
|
From date of enrollment until the end of treatment, up to approximately 6 months
|
All Phases: Progression free survival (PFS)
Time Frame: From date of enrollment until the end of treatment, up to approximately 6 months
|
Progression-free survival is defined as the time from the first dose to the date of disease progression or death (any cause), whichever occurs first
|
From date of enrollment until the end of treatment, up to approximately 6 months
|
All Phases: Pharmacokinetic Parameter Cmax of MDX2001
Time Frame: From date of enrollment until completion of the 6th cycle of treatment, up to approximately 6 months
|
Maximum observed plasma concentration
|
From date of enrollment until completion of the 6th cycle of treatment, up to approximately 6 months
|
All Phases: Pharmacokinetic parameter area under the curve (AUC(0-T)) of MDX2001
Time Frame: From date of enrollment until the completion of the 3rd cycle of treatment, up to approximately 3 months
|
Area under the plasma concentration versus time curve
|
From date of enrollment until the completion of the 3rd cycle of treatment, up to approximately 3 months
|
All Phases: Evaluation of MDX2001 immunogenicity
Time Frame: Baseline until end of study, up to approximately 9 months
|
The presence and persistence of anti-MDX2001 antibodies
|
Baseline until end of study, up to approximately 9 months
|
All Phases: Correlation between tumor antigen expression and anti-tumor activity of MDX2001
Time Frame: Baseline until the end of treatment, up to approximately 6 months
|
Relationship between H score cell surface target protein expression in tumor tissue at baseline and objective responses with MDX2001
|
Baseline until the end of treatment, up to approximately 6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Digestive System Neoplasms
- Liver Diseases
- Biliary Tract Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Kidney Neoplasms
- Carcinoma, Hepatocellular
- Endometrial Neoplasms
- Liver Neoplasms
- Biliary Tract Neoplasms
Other Study ID Numbers
- MDX-2001-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance